Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies
- Resource Type
- Journal
- Source
CLINICAL CANCER RESEARCH ; JUN 2003, 9 6, p2049-p2055, 7p.- Subject
- Language
- English
- ISSN
- 10780432